NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

Combining DCVax and CAR-T in the same production run seems like an efficient way to produce both given economies of scale.

Though has any trial combined them as combination therapy? My understanding was that CAR-T had limitations while DCVax would be superior for treating any solid tumors. So these do not seem like treatments that would be given for the same indication.

This may change in the future? Can anyone speculate so we may better understand the implications of EDEN and BATON with DCVax plus CAR-T?

We know the tumor microenvironment leads to T cell exhaustion.

Could the dendritic cell, paired ex vivo in BATON with T-cells, program a more effective T cell that persists longer in the patient?